Table 1.
Clinical and histopathological data, results of immunohistochemistry, p53 sequencing, and microsatellite analyses in 25 advanced gastric carcinomas
| Clinical data | |||||||||||||||||||||||||
| Patient ID | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 13 | 14 | 15 | 16 | 17 | 18 | 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| Sex | f | f | m | m | f | m | f | f | m | f | m | f | m | f | m | m | f | f | f | m | m | m | m | m | m |
| Age at diagnosis (years) | 57 | 49 | 62 | 46 | 61 | 42 | 51 | 46 | 32 | 45 | 55 | 47 | 48 | 49 | 44 | 43 | 44 | 33 | 54 | 50 | 40 | 56 | 60 | 34 | 36 |
| Overall survival (months) | 12.3 | 5.5 | 50.1 | 17.7 | 20.8 | 6.2 | 8.1 | 7.4 | 9.5 | 11.8 | 12.6 | 4.9 | 14.5 | 12.3 | 4.2 | 13.3 | 5 | 29.6 | 6.9 | 12.6 | 3 | 16.7 | 11.6 | 19.7 | 4.7 |
| Survival status | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 |
| Resection | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 1 | 0 |
| Histopathological data | |||||||||||||||||||||||||
| Localisation | co | an | co/an | ca | co | co | an | an | an | co | an | co/an | co | co/an | an | ca | an | an | co | an | co | an | co | co | ca |
| Lauren classification | d | d | d | i | i | d | d | i | d | d | d | d | i | i | d | i | d | d | d | d | d | i | d | d | d |
| Histological regression | |||||||||||||||||||||||||
| Regression score | 0 | 0 | 3 | 3 | 3 | 0 | 0 | 0 | 0 | 3 | 2 | 1a | 1b | 2 | 1a | 1b | 0 | 3 | 0 | 2 | 2 | 3 | 0 | 3 | 0 |
| Immunohistochemistry | |||||||||||||||||||||||||
| p53 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 1 | 1 | 0 |
| BAX | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Microsatellite analysis | |||||||||||||||||||||||||
| Mononcleotide markers | |||||||||||||||||||||||||
| BAT25 | |||||||||||||||||||||||||
| BAT26 | |||||||||||||||||||||||||
| Dinucleotide markers | |||||||||||||||||||||||||
| APC | LOH | LOH | LOH | LOH | LOH | LOH | LOH | LOH | LOH | ||||||||||||||||
| D17S250 | LOH | ||||||||||||||||||||||||
| D2S123 | MSI | MSI | MSI | MSI | |||||||||||||||||||||
| Pentanucleotide marker | |||||||||||||||||||||||||
| TP53.Alk | LOH | LOH | LOH | LOH | |||||||||||||||||||||
| Sequencing results | |||||||||||||||||||||||||
| p53 mutation | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 0 |
| Exon | 5 | 8 | 5 | 8 | 6 | 5 | 6 | 5 | |||||||||||||||||
| Codon | 177 | 282 | 162 | 273 | 213 | 175 | 220 | 178 | |||||||||||||||||
| Wild-type sequence | CCC | CGG | CGC | CGT | CGA | CGC | TAT | GCC | |||||||||||||||||
| Nucleotide substitution | TCC | CTG | CCC | TGT | CCA | CAC | TGT | GAC | |||||||||||||||||
| Allelic status of p53 mutation | het | het | het | het | het | het | het | het |
Sex: f, female; m, male. Survival status: 0, censored; 1, death. Localisation: ca, cardia; co, corpus; an, antrum. Histopathological classification according to Lauren29: i, intestinal type; d, diffuse type. Regression score according to the Japanese Research Society for Gastric Cancer classification of gastric carcinoma30: 0, grade 0; 1a, grade 1a; 1b, grade 1b; 2, grade 2; 3, grade 3. p53 immunohistochemistry: 0, negative; 1, positive (nuclear expression in >10% of tumour cells). BAX immunohistochemistry: 0, negative; 1, positive (cytoplasmatic expression in >5% of tumour cells). Allelic status of p53 mutation: het, heterozygeous; hemi, hemizygeous.